Cancer Research and Treatment

Original Articles

Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis: Jun Ho Ji, Young Saing Kim, Inkeun Park, Soon Il Lee, Rock Bum Kim, Joon Oh Park, Sung Yong Oh, In Gyu Hwang, Joung-Soon Jang, Haa-Na Song, Jung-Hun Kang; Cancer Res Treat. 2018;50(3):791-800. Published online August 23, 2017; DOI: https://doi.org/10.4143/crt.2017.044

Purpose
Although chemotherapy is recommended by various guidelines for advanced biliary tract cancer (BTC), the evidence supporting its use over best supportive care (BSC) is limited. The aim of this study was to investigate the survival benefit of chemotherapy over that of BSC in advanced BTC patients.
Materials and Methods
Advanced BTC patientswith a good performance status (Eastern CooperativeOncologyGroup [ECOG] 0-2) were eligible for the study. Data were retrospectively collected from four tertiary cancer centers and analyzed using propensity score matching (PSM). Of the 604 patients enrolled, 206 received BSC and 398 received chemotherapy. PSM analysis was performed using the following variables: age, ECOG status, carcinoembryonic antigen (CEA) level, white blood cell level, albumin level, total bilirubin level, and aspartate aminotransferase level. The sample size of each group was 164 patients after PSM. Median survival was compared between the two groups by using the Kaplan-Meier method, and prognostic factors were investigated using Cox proportional regression analysis.
Results
In post-PSM analysis, the respective median survival for the chemotherapy and BSC groups was dependent on the following prognostic factors: total population, 12.0 months vs. 7.5 months (p=0.001); locally advanced disease, 16.7 months vs. 13.4 months (p=0.490); cancer antigen 19-9 ≤ 100 IU/mL, 12.7 months vs. 10.6 months (p=0.330); and CEA ≤ 3.4 ng/mL, 17.1 months vs. 10.6 months (p=0.052).
Conclusion
Chemotherapy improved overall survival of patients with advanced BTC who had a good performance status. However, this survival benefit was not observed in BTC patients with locally advanced disease or with lower tumor marker. Individualized approach is needed for initiation of palliative chemotherapy in advanced BTC.

Citations

Citations to this article as recorded by

National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
Faisal Saud Dar, Zaigham Abbas, Irfan Ahmed, Muhammad Atique, Usman Iqbal Aujla, Muhammad Azeemuddin, Zeba Aziz, Abu Bakar Hafeez Bhatti, Tariq Ali Bangash, Amna Subhan Butt, Osama Tariq Butt, Abdul Wahab Dogar, Javed Iqbal Farooqi, Faisal Hanif, Jahanzai
World Journal of Gastroenterology.2024; 30(9): 1018. CrossRef
Treatment patterns and survival in older adults with unresected nonmetastatic biliary tract cancers
Ali Belkouz, Elise de Savornin Lohman, Jyothi R. Thumma, Bas Groot Koerkamp, Philip R. de Reuver, Martijn G.H. van Oijen, Cornelis J.A. Punt, Hari Nathan, Heinz-Josef Klümpen
Journal of Geriatric Oncology.2023; 14(3): 101447. CrossRef
Main causes of death in advanced biliary tract cancer
Kana Kimura‐Seto, Yasushi Kojima, Shiori Komori, Yuya Hisada, Yuki Otake, Yuka Yanai, Akiko Saito, Naoki Akazawa, Yasuo Tanaka, Chizu Yokoi, Mikio Yanase, Junichi Akiyama, Natsuyo Yamamoto, Kazuhiko Yamada
Cancer Medicine.2023; 12(9): 10889. CrossRef
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
Targeted Oncology.2023; 18(6): 837. CrossRef
Short- and Long-Term Survival of Metastatic Biliary Tract Cancer in the United States From 2000 to 2018
Van Nghiem, Sarah Wood, Rekha Ramachandran, Grant Williams, Darryl Outlaw, Ravikumar Paluri, Young-il Kim, Olumide Gbolahan
Cancer Control.2023;[Epub] CrossRef
Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map
Carolina Requeijo, Javier Bracchiglione, Nicolás Meza, Roberto Acosta-Dighero, Josefina Salazar, Marilina Santero, Adriana-G Meade, María Jesús Quintana, Gerardo Rodríguez-Grijalva, Anna Selva, Ivan Solà, Gerard Urrútia, Xavier Bonfill Cosp
Clinical Epidemiology.2023; Volume 15: 1069. CrossRef

8,158 View
213 Download
8 Web of Science
6 Crossref

Selection Criteria for Active Surveillance of Patients with Prostate Cancer in Korea: A Multicenter Analysis of Pathology after Radical Prostatectomy: Chang Wook Jeong, Sung Kyu Hong, Seok Soo Byun, Seong Soo Jeon, Seong Il Seo, Hyun Moo Lee, Hanjong Ahn, Dong Deuk Kwon, Hong Koo Ha, Tae Gyun Kwon, Jae Seung Chung, Cheol Kwak, Hyung Jin Kim; Cancer Res Treat. 2018;50(1):265-274. Published online April 14, 2017; DOI: https://doi.org/10.4143/crt.2016.477

Abstract PDF Supplementary Material PubReader ePub

Purpose
Korean patients with prostate cancer (PC) typically present with a more aggressive disease than patients in Western populations. Consequently, it is unclear if the current criteria for active surveillance (AS) can safely be applied to Korean patients. Therefore, this study was conducted to define appropriate selection criteria for AS for patients with PC in Korea.
Materials and Methods
We conducted a multicenter retrospective study of 2,126 patients with low risk PC who actually underwent radical prostatectomy. The primary outcome was an unfavorable disease, which was defined by non-organ confined disease or an upgrading of the Gleason score to ≥ 7 (4+3). Predictive variables of an unfavorable outcome were identified by multivariate analysis using randomly selected training samples (n=1,623, 76.3%). We compared our selected criteria to various Western criteria for the primary outcome and validated our criteria using the remaining validation sample (n=503, 23.7%).
Results
A non-organ confined disease rate of 14.9% was identified, with an increase in Gleason score ≥ 7 (4+3) of 8.7% and a final unfavorable disease status of 20.8%. The following criteria were selected: Gleason score ≤ 6, clinical stage T1-T2a, prostate-specific antigen (PSA) ≤ 10 ng/mL, PSA density < 0.15 ng/mL/mL, number of positive cores ≤ 2, and maximum cancer involvement in any one core ≤ 20%. These criteria provided the lowest unfavorable disease rate (11.7%) when compared to Western criteria (13.3%-20.7%), and their validity was confirmed using the validation sample (5.9%).
Conclusion
We developed AS criteria which are appropriate for Korean patients with PC. Prospective studies using these criteria are now warranted.

Citations

Citations to this article as recorded by

Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS‐JAPAN)
Takuma Kato, Ryuji Matsumoto, Akira Yokomizo, Yoichiro Tohi, Hiroshi Fukuhara, Yoichi Fujii, Keiichiro Mori, Takuma Sato, Junichi Inokuchi, Katsuyoshi Hashine, Shinichi Sakamoto, Hidefumi Kinoshita, Koji Inoue, Toshiki Tanikawa, Takanobu Utsumi, Takayuki
BJU International.2024; 134(4): 652. CrossRef
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry
Chris Bangma, Paul Doan, Lin Zhu, Sebastiaan Remmers, Daan Nieboer, Jozien Helleman, Monique J. Roobol, Mikio Sugimoto, Byung Ha Chung, Lui Shiong Lee, Mark Frydenberg, Laurence Klotz, Michael Peacock, Antoinette Perry, Anders Bjartell, Antti Rannikko, Mi
European Urology Oncology.2024;[Epub] CrossRef
Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database
Gyoohwan Jung, Jung Kwon Kim, Seong Soo Jeon, Jae Hoon Chung, Cheol Kwak, Chang Wook Jeong, Hanjong Ahn, Jae Young Joung, Tae Gyun Kwon, Sung Woo Park, Seok-Soo Byun
The World Journal of Men's Health.2023; 41(1): 110. CrossRef
The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance
Chang Wook Jeong
Journal of Urologic Oncology.2023; 21(2): 97. CrossRef
Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer
Sahyun Pak, Kyu-Won Jung, Eun-Hye Park, Young Hwii Ko, Young-Joo Won, Jae Young Joung
Investigative and Clinical Urology.2022; 63(2): 175. CrossRef
Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk
Yasmine Amrousy, Hesham Haffez, Doaa Abdou, Hanaa Atya
Molecular Medicine Reports.2022;[Epub] CrossRef
A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up
Sang Hun Song, Jung Kwon Kim, Hakmin Lee, Sangchul Lee, Sung Kyu Hong, Seok-Soo Byun
Investigative and Clinical Urology.2021; 62(1): 32. CrossRef
The clinical impact of strict criteria for active surveillance of prostate cancer in Korean population: Results from a prospective cohort
Jungyo Suh, Hyeong Dong Yuk, Minyong Kang, Bum Sik Tae, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak, Chang Wook Jeong
Investigative and Clinical Urology.2021; 62(4): 430. CrossRef
Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database
Kerri Beckmann, Aida Santaolalla, Jozien Helleman, Peter Carroll, Byung Ha Chung, Lui Shiong Lee, Antoinette Perry, Jose Rubio-Briones, Mikio Sugimoto, Bruce Trock, Riccardo Valdagni, Prokar Dasgupta, Mieke Van Hemelrijck, Oussama Elhage, Bruce Trock, Beh
European Urology Open Science.2021; 34: 47. CrossRef
Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance
Juhyun Park, Sangjun Yoo, Min Chul Cho, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Hyeon Jeong
Urologia Internationalis.2020; 104(3-4): 199. CrossRef
Current status and progress of focal therapy in Asia
Takumi Shiraishi, Osamu Ukimura
Current Opinion in Urology.2018; 28(6): 529. CrossRef
The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis
Kun Liu, Shuo Gu, Xuzhong Liu, Qing Sun, Yunyan Wang, Junsong Meng, Zongyuan Xu
Oncotarget.2017; 8(42): 72933. CrossRef

8,962 View
249 Download
9 Web of Science
12 Crossref

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea: Gebra Cuyun Carter, Anna Kaltenboeck, Jasmina Ivanova, Astra M. Liepa, Alexandra San Roman, Maria Koh, Narayan Rajan, Rebecca Cheng, Howard G. Birnbaum, Jong Seok Kim, Yung-Jue Bang; Cancer Res Treat. 2017;49(3):578-587. Published online September 12, 2016; DOI: https://doi.org/10.4143/crt.2016.001

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/orlocally recurrent, unresectable gastric cancer (MGC) in South Korea.
Materials and Methods
Thirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. Kaplan-Meier analysis was used to describe survival.
Results
Of 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current orformer smokers. The majority of tumorswere located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity indexwas 0.4 (standard deviation, 0.6). The most common comorbiditieswere chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second-line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients.
Conclusion
Most patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.

Citations

Citations to this article as recorded by

A Pilot Analysis of Capecitabine Plus PD‐1 Antibody as Maintenance Therapy in Advanced or Metastatic Gastric Cancer and the Prognostic Factors
Dong‐Liang Chen, Yan Hu, Dong‐Sheng Zhang, Feng‐Hua Wang
Advanced Therapeutics.2024;[Epub] CrossRef
A Novel Hematological Inflammation-Nutrition Score (HINS) and Its Related Nomogram Model to Predict Survival Outcome in Advanced Gastric Cancer Patients Receiving First-Line Palliative Chemotherapy
Chen Chen, Zehua Wang, Yanru Qin
Journal of Inflammation Research.2023; Volume 16: 2929. CrossRef
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort
Sylvain Manfredi, Marie Dior, Olivier Bouche, Emilie Barbier, Vincent Hautefeuille, Marielle Guillet, Justine Turpin, Vincent Bourgeois, Dall Osto Helene, Romain Desgrippes, Franck Audemar, Yann Molin, Christophe Locher, Thierry Chatellier, Thierry Lecomt
Cancer Medicine.2023; 12(5): 5341. CrossRef
A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation
Guk Jin Lee, Hyunho Kim, Sung Shim Cho, Hyung Soon Park, Ho Jung An, In Sook Woo, Jae Ho Byun, Ji Hyung Hong, Yoon Ho Ko, Der Sheng Sun, Hye Sung Won, Jong Youl Jin, Ji Chan Park, In-Ho Kim, Sang Young Roh, Byoung Yong Shim
Journal of Gastric Cancer.2023; 23(2): 315. CrossRef
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients
Hyun Cheol Chung, Yoon‐Koo Kang, Zhendong Chen, Yuxian Bai, Wan Zamaniah Wan Ishak, Byoung Yong Shim, Young Lee Park, Dong‐Hoe Koo, Jianwei Lu, Jianming Xu, Hong Jae Chon, Li‐Yuan Bai, Shan Zeng, Ying Yuan, Yen‐Yang Chen, Kangsheng Gu, Wen Yan Zhong, Shu
Cancer.2022; 128(5): 995. CrossRef
Clinical Impact of Prognostic Nutrition Index for Advanced Gastric Cancer Patients with Peritoneal Metastases Treated Nivolumab Monotherapy
Jungmin Lee, Soo Ho Choi, Jin Ho Baek, Dong Won Baek, Jong Gwang Kim, Byung Woog Kang
Chonnam Medical Journal.2022; 58(1): 24. CrossRef
A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma
Dena H. Jaffe, Joseph Gricar, Marc DeCongelio, deMauri S. Mackie
Thoracic Cancer.2022; 13(9): 1240. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care
K. Shimozaki, I. Nakayama, D. Takahari, D. Kamiimabeppu, H. Osumi, T. Wakatsuki, A. Ooki, M. Ogura, E. Shinozaki, K. Chin, K. Yamaguchi
ESMO Open.2021; 6(5): 100234. CrossRef
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
Hye Sook Han, Bum Jun Kim, Hee-Jung Jee, Min-Hee Ryu, Se Hoon Park, Sun Young Rha, Jong Gwang Kim, Woo Kyun Bae, Keun-Wook Lee, Do-Youn Oh, In-Ho Kim, Sun Jin Sym, So Yeon Oh, Hyeong Su Kim, Ji-Hye Byun, Dong Sook Kim, Young Ju Suh, Hyonggin An, Dae Young
Therapeutic Advances in Medical Oncology.2021;[Epub] CrossRef
Clinical management patterns of advanced and metastatic gastro‐oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom
Jacqueline Brown, Astra M. Liepa, Bela Bapat, Shweta Madhwani, Sylvie Lorenzen, Jesús García‐Foncillas, Sean D. Candrilli, James A. Kaye
European Journal of Cancer Care.2020;[Epub] CrossRef
Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
David Gómez-Ulloa, Mayur Amonkar, Smita Kothari, Winson Y. Cheung, Ian Chau, John R. Zalcberg, Núria Lara Suriñach, Alfredo Falcone
BMC Gastroenterology.2020;[Epub] CrossRef
Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil
Fernando Meton de Alencar Camara Vieira, Ana Paula Ornellas de Souza Victorino, Daniel de Iracema Gomes Cubero, Carlos Augusto de Mendonça Beato, Eimy Minowa, Guilherme Silva Julian, Diego Novick
Journal of Gastrointestinal Cancer.2019; 50(4): 780. CrossRef
Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer
Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee
Cancer Research and Treatment.2019; 51(1): 223. CrossRef
Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study
Sergei A. Tjulandin, Alexey A. Tryakin, Natalia S. Besova, Evgeniya Sholokhova, Jasmina I. Ivanova, Wendy Y. Cheng, Luke M. Schmerold, Philippe Thompson-Leduc, Diego Novick
Journal of Drug Assessment.2019; 8(1): 150. CrossRef
Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL‑17
Ran Chen, Qi‑Tian Chen, You‑Hong Dong
Oncology Letters.2019;[Epub] CrossRef
Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review
Miguel Quintana, José A. Toriz, Diego Novick, Kyla Jones, Brenda S. Botello, Juan Alejandro Silva
PharmacoEconomics - Open.2018; 2(2): 191. CrossRef
Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients
Michael Davidson, Catherine Cafferkey, Emily Frances Goode, Kyriakos Kouvelakis, Daniel Hughes, Pablo Reguera, Eleftheria Kalaitzaki, Clare Peckitt, Sheela Rao, David Watkins, Ian Chau, David Cunningham, Naureen Starling
Clinical Colorectal Cancer.2018; 17(3): 223. CrossRef

11,747 View
428 Download
18 Web of Science
18 Crossref

First
Prev
Page of 1
Next
Last

Search